115 related articles for article (PubMed ID: 20158339)
1. Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma.
Cui Y; Li T; Zhang D; Han J
Cancer Invest; 2010 Mar; 28(3):242-7. PubMed ID: 20158339
[TBL] [Abstract][Full Text] [Related]
2. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
[TBL] [Abstract][Full Text] [Related]
3. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
4. Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells.
Kocher HM; Sandle J; Mirza TA; Li NF; Hart IR
Gut; 2009 Feb; 58(2):271-84. PubMed ID: 18852256
[TBL] [Abstract][Full Text] [Related]
5. Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma.
Yeh TS; Tseng JH; Liu NJ; Chen TC; Jan YY; Chen MF
Arch Surg; 2005 Dec; 140(12):1184-90. PubMed ID: 16365240
[TBL] [Abstract][Full Text] [Related]
6. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.
Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Ozdogan M; Suleymanlar I; Balci MK; Griffith TS; Sanlioglu S
Pancreas; 2009 Mar; 38(2):154-60. PubMed ID: 18981952
[TBL] [Abstract][Full Text] [Related]
7. Expression of Ezrin, HGF, C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats.
Tan XG; Yang ZL
Hepatobiliary Pancreat Dis Int; 2010 Dec; 9(6):639-44. PubMed ID: 21134835
[TBL] [Abstract][Full Text] [Related]
8. High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome.
Einama T; Kagata Y; Tsuda H; Morita D; Ogata S; Ueda S; Takigawa T; Kawarabayashi N; Fukatsu K; Sugiura Y; Matsubara O; Hatsuse K
Pancreas; 2006 May; 32(4):376-81. PubMed ID: 16670630
[TBL] [Abstract][Full Text] [Related]
9. [Expression and significance of Ezrin gene in pancreatic carcinoma tissues].
Duan L; Li YX; Hu GH; Tang HH; Tao YM
Ai Zheng; 2008 Dec; 27(12):1337-40. PubMed ID: 19080005
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometrioid adenocarcinoma.
Yasuoka H; Tsujimoto M; Inagaki M; Kodama R; Tsuji H; Iwahashi Y; Mabuchi Y; Ino K; Sanke T; Nakamura Y
J Clin Pathol; 2012 May; 65(5):399-402. PubMed ID: 22412054
[TBL] [Abstract][Full Text] [Related]
11. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.
Masaki Y; Oka M; Ogura Y; Ueno T; Nishihara K; Tangoku A; Takahashi M; Yamamoto M; Irimura T
Hepatogastroenterology; 1999; 46(28):2240-5. PubMed ID: 10521973
[TBL] [Abstract][Full Text] [Related]
12. Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer.
Li YJ; Meng YX; Ji XR
Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):471-7. PubMed ID: 14599963
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
Nitori N; Ino Y; Nakanishi Y; Yamada T; Honda K; Yanagihara K; Kosuge T; Kanai Y; Kitajima M; Hirohashi S
Clin Cancer Res; 2005 Apr; 11(7):2531-9. PubMed ID: 15814630
[TBL] [Abstract][Full Text] [Related]
14. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
[TBL] [Abstract][Full Text] [Related]
15. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
[TBL] [Abstract][Full Text] [Related]
16. Analysis of c-kit protein expression in pancreatic neoplasms and its implication for prognosis.
Kimura W; Ma J; Takeshita A; Yamamoto T; Moriya T; Hirai I; Fuse A
Hepatogastroenterology; 2007 Dec; 54(80):2203-8. PubMed ID: 18265633
[TBL] [Abstract][Full Text] [Related]
17. Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.
Welsch T; Keleg S; Bergmann F; Bauer S; Hinz U; Schmidt J
Pancreas; 2009 Nov; 38(8):968-76. PubMed ID: 19672209
[TBL] [Abstract][Full Text] [Related]
18. Adhesion molecules as prognostic markers in pancreatic adenocarcinoma.
Torer N; Kayaselcuk F; Nursal TZ; Yildirim S; Tarim A; Nòyan T; Karakayali H
J Surg Oncol; 2007 Oct; 96(5):419-23. PubMed ID: 17874463
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
